Follow us on

Our blog

Jan 22, 2023

Lipogems Receives Approval from the FDA to Study the Lipogems System for Knee Osteoarthritis

Knee osteoarthritis is a crippling disease for millions of people. In some cases, conservative options fail to control a patient’s pain, but they are not ready and/or do not qualify for a total knee replacement. The is a segment of patients that fall in the treatment gap between traditional conservative therapies and surgery.

Lipogems is a device that has received FDA 510(k) clearance to process adipose tissue for general applications in orthopaedics, arthroscopy, and nine other specialties.

Lipogems has obtained approval by the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) study for the treatment of knee osteoarthritis (OA). This study, is designed to test the safety and efficacy of the Lipogems system when compared to corticosteroids over a period of 12 months, and will hopefully result in a specific indication for Lipogems in Knee OA. The Lipogems' ARISE FDA IDE Study will enroll patients in 20 sites across the U.S.

Lipogems decided to pursue this specific indication based on the positive results seen in 30+ independent peer-reviewed publications with up to 3 years follow-up evaluating pain, function, quality of life, and economic advantages in patients treated with Lipogems' Microfragmented Fat (MFat) injections for knee osteoarthritis. The completion of this study and anticipated approval in the setting of knee osteoarthritis will permit Lipogems to educate directly to physicians and consumers for the treatment of this pathology.

The Lipogems system has been used in multiple pathologies and is supported by 115+ independent peer reviewed publications. On January 13, 2023 Lipogems announced that it enrolled the first patient in the ARISE Study. Learn more about Lipogems here.


Lipogems Announces First Patient Enrolled in the U.S. ARISE study for the Treatment of Knee Osteoarthritis at (Accessed January 22, 2023).

Lipogems® Receives IDE Approval From The U.S. FDA To Begin A Pivotal Clinical Study On The Safety And Effectiveness Of The Lipogems System For The Treatment of Knee Osteoarthritis (Accessed January 22, 2023).

More Articles

Mar 02, 2023

Non-surgical Treatments for Lateral Epicondylitis and Medial Epicondylitis: Tenex versus Platelet-Rich Plasma

Medial epicondylitis (golfer’s elbow) and lateral epicondylitis (tennis elbow) are among the most common elbow pathologies affecting people aged between 40 and 50 years. Although epicondylitis is often a self-limiting

Read More
Feb 06, 2023

What is A2M and what is the data for A2M in Osteoarthritis?

Osteoarthritis is common problem causing joint disease. Alpha-2-macroglobulin (A2M), a naturally occurring macromolecule that is found in the blood serum, and studies have demonstrated that Alpha-2-Macroglobulin, or

Read More